Paris (Feb / PRNewswire) – – This cutting-edge technology helps radiologists interpret screening mammograms, allowing them to diagnose breast cancer earlier and more accurately.
Therapixel announced today that MammoScreen (TM) has successfully received the CE mark. After this AI solution received US FDA approval in March 2020 for commercial distribution in the US, it is now also available in the European market.
MammoScreen (TM) automatically scans for screening mammograms and shows suspicious mammograms and lesions to the radiologist. Depending on the probability of malice and the level of confidence in the algorithm, the software assigns a unique “MammoScreen Score (TM)” that ranges from 1 to 10.
A clinical study conducted in 2019 and published in Radiology: AI showed that radiologists supported by MammoScreen (TM) work better than without software.
In addition, MammoScreen (TM) helps increase the speed of interpretation of benign images, giving doctors more time to focus on cases that require more attention.
The MammoScreen (TM) has already been installed in 14 hospitals and radiological consultations in France for clinical evaluations and has aroused great enthusiasm among radiologists. Doctors consider it an intuitive and easy-to-use tool that gives them confidence in their interpretation and prevents them from overlooking cancers.
Breast cancer is one of the most common and deadly types of cancer in women worldwide, and affects 1 in eight women in their lifetime. The sooner this disease is diagnosed, the more effective the treatment will be.
“We are proud to have received the CE mark. This brings us one step closer to our goal of reducing the burden of breast cancer worldwide by improving breast cancer screening,” said Pierre Fillard, founder and director. Therapixel scientist.
“I am confident that MammoScreen (TM) will not only improve the performance of radiologists, but will also improve the patient experience by calming women more quickly,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.
Therapixel is a French company specializing in the development and marketing of AI-driven medical imaging software with the goal of providing relevant information to healthcare professionals at the right time. As the winner of the Digital Mammography DREAM Challenge in 2017, the global competition for the detection of breast cancer with AI, Therapixel developed MammoScreen (TM), a software that aids in the interpretation of screening mammograms. With MammoScreen (TM), even experienced radiologists can improve their performance, feel more confident in their judgment, and reassure women more quickly. For more information, see www.mammoscreen.com
Inquiries and contact:
Logo – mma.prnewswire.com/media/1418252/Therapixel_Logo.jpg